The round was co-led by GV and TQ Ventures to support international expansion.
"Our mission is to make legal services accessible for everyone while helping consumer lawyers and small firms rediscover the joy of practicing law. This funding will accelerate our US launch, where demand for faster, more affordable legal services is significant. By augmenting the work of human lawyers with our technology, we’re addressing a critical need in the US market and unlocking new opportunities for millions of US attorneys."
Balderton Capital led the pre-seed round, which will fund the development of continual learning models for Proxy assistants.
"Imagine an agent that keeps growing and learning whenever you teach them something new. Over time, the agent will take on mundane tasks allowing you to focus on higher-level tasks that are more impactful and also more enjoyable. The key to our approach is the ability for Proxy to learn and memorise tasks on the job, remembering them for the long term and being able to use its memories to extrapolate to new tasks – just as a person would. Our mission at Convergence is to build new, foundationally different technologies that are a clear pathway to useful intelligence. Balderton shares our vision deeply and we are looking forward to turning it into a reality with them."
The seed extension round was led by Balderton and HV Capital alongside company founder Simon Beckerman.
"Since stepping into the CEO role, Marie has taken DELLI’s growth to the next level, and the momentum is remarkable. Doubling down on our investment was a no-brainer, and I’m excited for what’s to come. DELLI has been one step ahead of shifting consumer behaviours around food and drink, and as more and more people opt for quality, independent craftsmanship over mass-produced and ultra-processed products, I have no doubt DELLI’s growth will continue to soar."
The round was led by Balderton Capital with backing from TQ Ventures, Earlybird, and Seedcamp.
"Tilt has an incredibly exciting journey ahead. We are thrilled to have the backing of the exceptional team at Balderton Capital, along with our existing investors in this round. This support will enable us to scale the Tilt platform, expand the team, and deepen our engagement with our growing community,"
The Series C round was co-led by R42 Group and Atomico to support clinical trials for rare disease treatments.
"It is truly a pivotal time at Healx. By December 2024, we will advance HLX-1502 into a Phase 2 clinical trial in patients with NF1 both for plexiform neurofibroma, a genetic condition with limited treatment options and for cutaneous neurofibroma, for which there are no FDA approved options. We are also generating important preclinical data for multiple additional compounds identified using our novel generative AI drug discovery engine. Those compounds target rare diseases with significant unmet needs, including additional nerve-related tumor disorders, autosomal dominant polycystic kidney disease and neurodevelopmental disorders such as Angelman syndrome."
